| Riverside Family Medicine Pc | |
|
3129 Blattner Dr Cape Girardeau MO 63703-6364 | |
| (573) 335-0166 | |
| (573) 335-7942 |
| Full Name | Riverside Family Medicine Pc |
|---|---|
| Speciality | Family Medicine |
| Location | 3129 Blattner Dr, Cape Girardeau, Missouri |
| Authorized Official Name and Position | James E Palen (PHYSICIAN) |
| Authorized Official Contact | 5733350166 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Riverside Family Medicine Pc 3129 Blattner Dr Cape Girardeau MO 63703-6364 Ph: (573) 335-0166 | Riverside Family Medicine Pc 3129 Blattner Dr Cape Girardeau MO 63703-6364 Ph: (573) 335-0166 |
| NPI Number | 1255610150 |
|---|---|
| Provider Enumeration Date | 08/09/2011 |
| Last Update Date | 08/09/2011 |
| Medicare PECOS PAC ID | 7012189715 |
|---|---|
| Medicare Enrollment ID | O20110930000136 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255610150 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Pamela K Himstedt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164690236 PECOS PAC ID: 7517045065 Enrollment ID: I20080423000624 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Provider Name | James R Palen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598902728 PECOS PAC ID: 7517012230 Enrollment ID: I20091105000159 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Provider Name | James E Palen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114973161 PECOS PAC ID: 3173535127 Enrollment ID: I20100108000181 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Provider Name | Lori Ann Moyers |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023145125 PECOS PAC ID: 4385716034 Enrollment ID: I20100901000070 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Provider Name | Karen M Abt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144672577 PECOS PAC ID: 8224322920 Enrollment ID: I20160803001010 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Provider Name | Valerie Ann Campbell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386094241 PECOS PAC ID: 6103110697 Enrollment ID: I20160805001560 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Provider Name | Amanda L Wareing |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164932448 PECOS PAC ID: 6800162355 Enrollment ID: I20171027000772 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
| Provider Name | Cassandra L Doss |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649747403 PECOS PAC ID: 6103160270 Enrollment ID: I20181129002561 |
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
News Archive
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.
Almost 1 million young adults have signed on to new health insurance policies, government statistics released Wednesday show. Government officials credit the new federal health care law for making that possible. A survey by the Centers for Disease Control and Prevention found that the number of Americans ages 19 to 25 without insurance fell to 9.1 million in the first three months of 2011 from 10 million in 2010.
Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that for fiscal 2011, the Company expects revenue to be in the range of $71 to $82 million, net profit to be $27 to $31 million and earnings per share to be $0.97 to $1.12, based upon 28 million shares outstanding.
According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%.
› Verified 9 days ago
Johns Healthcare Services Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2001 Independence St Ste A, Cape Girardeau, MO 63703 Phone: 573-304-3143 Fax: 573-334-0493 | |
Cross Trails Medical Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2430 Golden Street, Cape Girardeau, MO 63703 Phone: 573-339-1196 Fax: 573-339-9378 | |
Auburn Surgery Center Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 300 S Mount Auburn Rd, Ste 200, Cape Girardeau, MO 63703 Phone: 573-332-7881 Fax: 573-651-4431 | |
Midtown Family Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 24 N Sprigg St, Cape Girardeau, MO 63701 Phone: 573-332-7992 Fax: 573-332-7998 | |
Kenneth A Decoursey, Md Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1723 Broadway St, Suite 120, Cape Girardeau, MO 63701 Phone: 573-334-7194 Fax: 573-334-4937 | |
Immediate Healthcare, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1702 N Kingshighway St, Cape Girardeau, MO 63701 Phone: 573-339-2000 Fax: 573-339-1876 | |
Immediate Convenient Care Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1702 N Kingshighway St, Cape Girardeau, MO 63701 Phone: 573-339-2000 |